Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

BMS CA209651: An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination with Ipilimumab vs Extreme Study Regimen (cetuximab +cisplatin/carboplatin + fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcino
Brief Description  
Primary: To compare progression free survival as determined by independent radiology committee and overall survival of nivolumab combined with ipimumab to EXTREME regimen as first line treatment in subjects with recurrent or metastatic SCCHN. Secondary: To compare the objective response rate, as determined by IRC.To compare time to symptom deterioration as assessed using the 10-item Functional Assessment of Cancer Therapy-Head & Neck Symptom Index. To evaluated whether PD-L1 expression is a pr
Who may be Eligible  
Please contact us for eligibility criteria.
Lip, Oral Cavity and Pharynx
Start Date  
IRB Number  
Principal Investigator  
Sumrall, Ashley Love
Contact Name  
Carrie Syfert

For More Information, Contact  Carrie  , Syfert
Phone:  980-442-2384 Fax:    
Email:  Carrie.Syfert@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204